154 related articles for article (PubMed ID: 25542473)
1. Comparison of the Roche Cobas(®) 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for Detection of High-Risk Human Papillomavirus Genotypes in Women undergoing treatment for cervical dysplasia.
Phillips S; Garland SM; Tan JH; Quinn MA; Tabrizi SN
J Clin Virol; 2015 Jan; 62():63-5. PubMed ID: 25542473
[TBL] [Abstract][Full Text] [Related]
2. EUROarray human papillomavirus (HPV) assay is highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.
Cornall AM; Poljak M; Garland SM; Phillips S; Machalek DA; Tan JH; Quinn MA; Tabrizi SN
Eur J Clin Microbiol Infect Dis; 2016 Jun; 35(6):1033-6. PubMed ID: 27048314
[TBL] [Abstract][Full Text] [Related]
3. Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus.
Yu S; Kwon MJ; Lee EH; Park H; Woo HY
J Med Virol; 2015 Sep; 87(9):1587-93. PubMed ID: 25914215
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Roche Cobas® 4800 HPV assay to Roche Amplicor for detection of high-risk human papillomavirus.
Phillips S; Cornall AM; Machalek DA; Garland SM; Bateson D; Garefalakis M; Tabrizi SN
Eur J Clin Microbiol Infect Dis; 2016 Aug; 35(8):1305-7. PubMed ID: 27177752
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Cobas 4800 Human Papillomavirus test against a combination of the Amplicor Human Papillomavirus and the Linear Array tests for detection of HPV types 16 and 18 in cervical samples.
Martínez SB; Palomares JC; Artura A; Parra M; Cabezas JL; Romo JM; Martín-Mazuelos E
J Virol Methods; 2012 Mar; 180(1-2):7-10. PubMed ID: 22197189
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of the Roche Cobas HPV Test With the Hybrid Capture 2 Test for the Detection of High-Risk Human Papillomavirus Genotypes.
Levi AW; Bernstein JI; Hui P; Duch K; Schofield K; Chhieng DC
Arch Pathol Lab Med; 2016 Feb; 140(2):153-7. PubMed ID: 26910220
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.
Sandri MT; Lentati P; Benini E; Dell'Orto P; Zorzino L; Carozzi FM; Maisonneuve P; Passerini R; Salvatici M; Casadio C; Boveri S; Sideri M
J Clin Microbiol; 2006 Jun; 44(6):2141-6. PubMed ID: 16757611
[TBL] [Abstract][Full Text] [Related]
8. Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
Nakamura M; Nakade K; Orisaka S; Iwadare J; Mizumoto Y; Fujiwara H
Am J Clin Pathol; 2019 Feb; 151(3):263-269. PubMed ID: 30260388
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance.
Halfon P; Trepo E; Antoniotti G; Bernot C; Cart-Lamy P; Khiri H; Thibaud D; Marron J; Martineau A; Pénaranda G; Benmoura D; Blanc B;
J Clin Microbiol; 2007 Feb; 45(2):313-6. PubMed ID: 17122007
[TBL] [Abstract][Full Text] [Related]
10. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA Genotyping assay to screen the discordant results.
Mo LZ; Monnier-Benoit S; Kantelip B; Petitjean A; Riethmuller D; Prétet JL; Mougin C
J Clin Virol; 2008 Feb; 41(2):104-10. PubMed ID: 18036888
[TBL] [Abstract][Full Text] [Related]
11. CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology.
Pesic A; Krings A; Hempel M; Preyer R; Chatzistamatiou K; Agorastos T; Kaufmann AM
Virol J; 2019 Jul; 16(1):92. PubMed ID: 31337408
[TBL] [Abstract][Full Text] [Related]
12. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
13. Comparison of urine, self-collected vaginal swab, and cervical swab samples for detecting human papillomavirus (HPV) with Roche Cobas HPV, Anyplex II HPV, and RealTime HR-S HPV assay.
Cho HW; Ouh YT; Hong JH; Min KJ; So KA; Kim TJ; Paik ES; Lee JW; Moon JH; Lee JK
J Virol Methods; 2019 Jul; 269():77-82. PubMed ID: 30998958
[TBL] [Abstract][Full Text] [Related]
14. Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.
Demarco M; Carter-Pokras O; Hyun N; Castle PE; He X; Dallal CM; Chen J; Gage JC; Befano B; Fetterman B; Lorey T; Poitras N; Raine-Bennett TR; Wentzensen N; Schiffman M
J Clin Microbiol; 2018 May; 56(5):. PubMed ID: 29491018
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results.
Stevens MP; Garland SM; Rudland E; Tan J; Quinn MA; Tabrizi SN
J Clin Microbiol; 2007 Jul; 45(7):2130-7. PubMed ID: 17494721
[TBL] [Abstract][Full Text] [Related]
16. Anyplex II HPV test in detection and follow-up after surgical treatment of CIN2+ lesions.
Bottari F; Iacobone AD; Radice D; Preti EP; Preti M; Franchi D; Piana AF; Sandri MT; Passerini R
J Med Virol; 2021 Nov; 93(11):6340-6346. PubMed ID: 33565607
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
Chung HS; Hahm C; Lee M
J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
De Francesco MA; Gargiulo F; Schreiber C; Ciravolo G; Salinaro F; Manca N
J Virol Methods; 2008 Jan; 147(1):10-7. PubMed ID: 17854914
[TBL] [Abstract][Full Text] [Related]
19. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear.
Monsonego J; Bohbot JM; Pollini G; Krawec C; Vincent C; Merignargues I; Haroun F; Sednaoui P; Monfort L; Dachez R; Syrjänen K
Gynecol Oncol; 2005 Oct; 99(1):160-8. PubMed ID: 16023184
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H).
Cubie HA; Canham M; Moore C; Pedraza J; Graham C; Cuschieri K
J Clin Pathol; 2014 Jun; 67(6):458-63. PubMed ID: 24436334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
